ADCs: The Next Phase of Innovation

Antibody-drug conjugates (ADCs) are evolving rapidly, surpassing traditional limitations with high drug-to-antibody ratios (DARs), multispecific designs, and novel payloads. While these advancements offer significant therapeutic potential, they also introduce challenges such as systemic clearance, design complexity, regulatory hurdles, and, most critically, manufacturability. This report, developed with Cytiva, provides an indepth analysis of the latest innovations shaping the ADC landscape and the key factors needed to transform these breakthroughs into viable therapies.

Key Insights:

• Innovation Landscape – An exploration of pipeline activity for high DARs, multispecific ADCs, and novel payloads, highlighting their ability to expand therapeutic possibilities.

• Barriers to Innovation – Insights into the scientific, commercial, manufacturing, and regulatory challenges that may hinder market entry.

• Path to Success – Analyzing how CDMOs and industry stakeholders must adapt to translate cutting-edge innovations into scalable, commercially viable therapies.